Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Emerging biologic subsets and new prognostic markers are significantly and adversely
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …

MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …

MYC is a potent oncogene initially identified as the target of the t (8; 14)(q24; q32)
chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified …

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and
clinical behavior. Patients typically present with persistent painless lymphadenopathy, but …

In this review, the authors describe a novel mechanism for control of MYC expression that
involves a four-stranded DNA structure, termed a G-quadruplex, amenable to small …

MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most
studies have focused on MYC translocations but there is little information regarding the …

Hematopoiesis is a process capable of generating millions of cells every second, as
distributed in many cell types. The process is regulated by a number of transcription factors …

High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements,
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …

Double-hit lymphoma (DHL) is a subgroup of aggressive lymphomas with both MYC and
BCL2 gene rearrangements, characterised by a rapidly progressing clinical course that is …